No description available.

Problem gambling is the subclinical form of pathological gambling and both are characterized by difficulties in the limiting of money and time spent on gambling. Genetic and personality factors have been implicated in gambling disorders (PG). As PG is classified as an impulse-control disorder, the serotonin (5-HT) system has been suggested to be involved. We sought to better understand the complex relationship between personality traits, PG, and 5-HT genes. We investigated ten 5-HT candidate genes for association with PG and personality traits. We also examined personality traits for association with PG. We found that MAOA and HTR3A haplotypes were associated with Agreeableness and Conscientiousness personality domains, PG was associated with high Neuroticism and low Conscientiousness scores, and the MAOA gene may play a role in PG. Our findings contribute to the better understanding of how 5-HT genes may be involved in the neurobiological mechanisms underlying PG and personality.

Problem gambling is the subclinical form of pathological gambling and both are characterized by difficulties in the limiting of money and time spent on gambling. Genetic and personality factors have been implicated in gambling disorders (PG). As PG is classified as an impulse-control disorder, the serotonin (5-HT) system has been suggested to be involved. We sought to better understand the complex relationship between personality traits, PG, and 5-HT genes. We investigated ten 5-HT candidate genes for association with PG and personality traits. We also examined personality traits for association with PG. We found that MAOA and HTR3A haplotypes were associated with Agreeableness and Conscientiousness personality domains, PG was associated with high Neuroticism and low Conscientiousness scores, and the MAOA gene may play a role in PG. Our findings contribute to the better understanding of how 5-HT genes may be involved in the neurobiological mechanisms underlying PG and personality.

Abstract Chlamydia pneumoniae is an obligate intracellular gram-negative bacterium, which causes respiratory infections in humans and may participate in the development of chronic diseases like atherosclerosis, chronic obstructive lung disease, adult-onset asthma and late-onset Alzheimer’s disease. It can infect various cell types, e.g. vascular endothelial cells, smooth muscle cells and monocyte-derived macrophages in vitro. It has been speculated that circulating macrophages disseminate the infection in the body, and that genetically susceptible individuals become chronically infected. Quantification of C. pneumoniae growth inside cultured cells is needed when studying e.g. the effect of drugs or host cell factors on infectivity and replication. Conventionally this has been done by immunofluorescence staining and microscopic counting of chlamydial inclusions. However, this method is usable only if the cell numbers do not fluctuate in cell culture vials and the inclusions are uniform. In macrophages, inclusions are often aberrant, their sizes vary and multiple inclusions are also seen. Therefore we developed a new method based on the real-time PCR quantification of chlamydial genomes adjusted to the number of human genomes and used it to quantify the exact amounts of C. pneumoniae in infected cells. The susceptibility of monocyte-macrophages from healthy individuals to C. pneumoniae infection in vitro was studied first. Intracellular growth of C. pneumoniae was used as an indicator of susceptibility to infection, and it was compared to serum levels of CRP, soluble CD14, human HSP-IgG, human HSP-IgA, C. pneumoniae IgG and IgA antibodies. The growth of C. pneumoniae in infected macrophages was highly variable, ranging from 0 to 638 chlamydial genomes per human genome. C. pneumoniae growth associated positively with serum C. pneumoniae IgA (titer ≥10) and hHSP-IgG and negatively with soluble CD14 concentration. The association between chlamydial IgA antibodies, hHSP-IgG and C. pneumoniae growth was statistically significant only among men. Age did not correlate with the growth. Therefore we hypothesize that persons whose macrophages cannot restrict the growth of C. pneumoniae are more prone to chronic infection by this agent. In the next study, we evaluated the effects of innate immunity genes CD14 -260 C>T, TLR2 Arg753Gln, TLR4 Asp299Gly, LBP Phe436Leu and IL-6 -174 G>C polymorphisms on C. pneumoniae growth in human macrophages in vitro. The growth of C. pneumoniae was highest in CD14 -260 C>T TT genotype cells and the difference to CC or CT genotype was statistically significant. The G-allele of the IL6 -174 G>C polymorphism had a positive influence on chlamydial growth; the difference was statistically significant only between CC and GC genotypes. TLR2 Arg753Gln, TLR4 Asp299Gly, LBP Phe436Leu polymorphisms showed no effect on chlamydial growth.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Estudos demonstram a associação de alterações da apolipoproteína E (ApoE) e do receptor do LDL (RLDL) com a ocorrência de doenças cardiovasculares e dislipidemia. O objetivo principal deste trabalho foi investigar a associação entre genótipos diferenciais da ApoE e do RLDL com a persistência de alterações de variáveis lipídicas em indivíduos jovens acompanhados há 28 anos no Estudo do Rio de Janeiro (ERJ). Através de um estudo longitudinal, tipo coorte, investigou-se 56 indivíduos (35M) em três avaliações. Em A1 (13.301.53 anos), A2 (22.091.91 anos) e A3 (31.231.99). Nas três ocasiões foi realizada avaliação clínica. Em A2 e A3 foram dosados colesterol total, HDL, LDL e triglicerídeos. Em A3 acrescentou-se o estudo dos polimorfismos genéticos da ApoE e do RLDL. Os fragmentos de interesse neste estudo foram amplificados por PCR (polymerase chain reaction) e os genótipos foram identificados através de reações de restrição. As frequências genotípicas de ApoE foram ε3/ε3 (62,5%), ε3/ε4 (25%), ε2/ε3 (5,4%) ,ε2/ε4 (5,4%) e ε4/ε4 (1,8%) e para os genótipos de RLDL foram AA (85,7%), AT (12,5%) e TT (1,8%). O genótipo ε2/ε2 não foi observado. A análise da distribuição dos genótipos de ApoE segundo a permanência de dislipidemia mostrou que todos os indivíduos com genótipo de ApoE dos tipos ε2/ε4 e ε4/ε4 mantiveram pelo menos um lípide alterado em A2 e A3 entretanto, todos os indivíduos com genótipo de ApoE do tipo ε2/ε3 não apresentaram lípides alterados em A2 e A3. Para o genótipo do RLDL não houve diferença significativa. Quando analisadas isoladamente, não foi identificado nenhum resultado significativo em A2 e/ou A3 associado a estes genótipos. O polimorfismo do gene da ApoE esteve associado à permanência de dislipidemia em indivíduos jovens acompanhados em estudo de seguimento longitudinal / Studies have shown the association of changes in the apolipoprotein E (ApoE) and LDL receptor (LDLR) with the occurrence of cardiovascular diseases and dyslipidemia. The objective of this study was to investigate the association between different ApoE genotypes and LDLR with the persistence of changes in lipid variables in young individuals followed-up 28 years in the study of Rio de Janeiro (ERJ). Through a longitudinal study cohort, 56 subjects (35M) in A1(13.30 1.53 years), A2(22.09 1.91 years) and A3(31.23 1.99) were investigated. On all three occasions clinical evaluation was conducted. In A2 and A3: total cholesterol, HDL, LDL and triglycerides. In A3 was added to the study of genetic polymorphisms of the ApoE and LDLR. The fragments of interest in this study were amplified by PCR (polymerase chain reaction) and the genotypes were identified by reaction with the restriction enzyme HhaI and HaeIII for ApoE and LDLR polymorphisms, respectively. ApoE genotypes were identified as ε3/ε3 (62.5%), ε3/ε4 (25%), ε2/ε3 (5.4%), ε2/ε4 (5.4%) and ε4/ε4 (1.8%) and the LDLR genotypes identified as AA (85.7%), AT (12.5%) and TT (1.8%). ε2/ε2 genotype was not observed. The analysis of the distribution of ApoE and LDLR genotypes according to the permanence of the dyslipidemia in the study sample showed that all individuals with the ApoE genotype ε2/ε4 and ε4/ε4 kept at least one lipid changes in A2 and A3 and all individuals ApoE genotype ε2/ε3 had not altered lipids in A2 and A3, while for RLDL genotype no difference was found. When analyzed individually, no lipid variable altered in A2 and/or A3, associated with these genotypes, were found. The ApoE gene polymorphism was associated with the permanence of dyslipidemia in young individuals in a longitudinal follow-up study

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Estudos demonstram a associação de alterações da apolipoproteína E (ApoE) e do receptor do LDL (RLDL) com a ocorrência de doenças cardiovasculares e dislipidemia. O objetivo principal deste trabalho foi investigar a associação entre genótipos diferenciais da ApoE e do RLDL com a persistência de alterações de variáveis lipídicas em indivíduos jovens acompanhados há 28 anos no Estudo do Rio de Janeiro (ERJ). Através de um estudo longitudinal, tipo coorte, investigou-se 56 indivíduos (35M) em três avaliações. Em A1 (13.301.53 anos), A2 (22.091.91 anos) e A3 (31.231.99). Nas três ocasiões foi realizada avaliação clínica. Em A2 e A3 foram dosados colesterol total, HDL, LDL e triglicerídeos. Em A3 acrescentou-se o estudo dos polimorfismos genéticos da ApoE e do RLDL. Os fragmentos de interesse neste estudo foram amplificados por PCR (polymerase chain reaction) e os genótipos foram identificados através de reações de restrição. As frequências genotípicas de ApoE foram ε3/ε3 (62,5%), ε3/ε4 (25%), ε2/ε3 (5,4%) ,ε2/ε4 (5,4%) e ε4/ε4 (1,8%) e para os genótipos de RLDL foram AA (85,7%), AT (12,5%) e TT (1,8%). O genótipo ε2/ε2 não foi observado. A análise da distribuição dos genótipos de ApoE segundo a permanência de dislipidemia mostrou que todos os indivíduos com genótipo de ApoE dos tipos ε2/ε4 e ε4/ε4 mantiveram pelo menos um lípide alterado em A2 e A3 entretanto, todos os indivíduos com genótipo de ApoE do tipo ε2/ε3 não apresentaram lípides alterados em A2 e A3. Para o genótipo do RLDL não houve diferença significativa. Quando analisadas isoladamente, não foi identificado nenhum resultado significativo em A2 e/ou A3 associado a estes genótipos. O polimorfismo do gene da ApoE esteve associado à permanência de dislipidemia em indivíduos jovens acompanhados em estudo de seguimento longitudinal / Studies have shown the association of changes in the apolipoprotein E (ApoE) and LDL receptor (LDLR) with the occurrence of cardiovascular diseases and dyslipidemia. The objective of this study was to investigate the association between different ApoE genotypes and LDLR with the persistence of changes in lipid variables in young individuals followed-up 28 years in the study of Rio de Janeiro (ERJ). Through a longitudinal study cohort, 56 subjects (35M) in A1(13.30 1.53 years), A2(22.09 1.91 years) and A3(31.23 1.99) were investigated. On all three occasions clinical evaluation was conducted. In A2 and A3: total cholesterol, HDL, LDL and triglycerides. In A3 was added to the study of genetic polymorphisms of the ApoE and LDLR. The fragments of interest in this study were amplified by PCR (polymerase chain reaction) and the genotypes were identified by reaction with the restriction enzyme HhaI and HaeIII for ApoE and LDLR polymorphisms, respectively. ApoE genotypes were identified as ε3/ε3 (62.5%), ε3/ε4 (25%), ε2/ε3 (5.4%), ε2/ε4 (5.4%) and ε4/ε4 (1.8%) and the LDLR genotypes identified as AA (85.7%), AT (12.5%) and TT (1.8%). ε2/ε2 genotype was not observed. The analysis of the distribution of ApoE and LDLR genotypes according to the permanence of the dyslipidemia in the study sample showed that all individuals with the ApoE genotype ε2/ε4 and ε4/ε4 kept at least one lipid changes in A2 and A3 and all individuals ApoE genotype ε2/ε3 had not altered lipids in A2 and A3, while for RLDL genotype no difference was found. When analyzed individually, no lipid variable altered in A2 and/or A3, associated with these genotypes, were found. The ApoE gene polymorphism was associated with the permanence of dyslipidemia in young individuals in a longitudinal follow-up study

A leishmaniose visceral constitui grave doença infecciosa causada por um protozoário parasita intracelular obrigatório. Alguns fatores podem alterar a gravidade das manifestações clínicas, sendo um deles a predisposição genética. Este estudo investigou polimorfismos dos genes TGFB1, IL8 e IL6, que são citocinas relacionadas com o desencadeamento e a gravidade da doença, visando identificar fatores de susceptibilidade. Os polimorfismos TGFB1 -509 C/T e TGFB1 +869 T/C, IL8 -251A/T e IL6 -174G/C foram analisados por PCR-RFLP, em 198 pacientes com leishmaniose visceral (LV), 98 indivíduos com infecção assintomática (teste de hipersensibilidade tardia - DTH+) e 100 indivíduos sem evidências de infecção (DTH-). O alelo T na posição -509 do gene TGFB1 conferiu risco duas vezes maior de desenvolver LV ou ser positivo para o teste DTH (p = 0,007, OR = 1,9 [1,19-3,02]), em comparação com indivíduos DTH-. Os resultados sugerem uma associação do polimorfismo TGFB1 -509C/T com a susceptibilidade à LV, podendo contribuir para o desencadeamento da doença clínica. / Visceral leishmaniasis is a serious protozoan infectious disease caused by an obligate intracellular parasite. Some factors can affect the severity of the clinical manifestations; one of which is genetic susceptibility. This study investigated polymorphisms in the TGFB1, IL8 and IL6 genes, which are cytokines related with the onset and severity of the disease, to look for genetic susceptibility factors. Polymorphisms at TGFB1 -509C/T and +869T/C, and IL8 - 251A/T and IL6 -174G/C were analyzed by a PCR-RFLP technique, in 198 patients with Visceral Leishmaniasis (VL), 98 individuals with asymptomatic infection (positive delayed-type hypersensitivity, DTH+) and 100 individuals with no evidence of infection (DTH-). The T allele of the TGFB1 polymorphism in position -509C/T conferred a two risk fold to develop LV or to be DTH+ (p=0.007; OR=1.9 [1.19 - 3.02]) when compared with DTH- individuals. We suggest the TGFB1 -509C/T polymorphism is associated with susceptibility to LV and may contribute to development of the clinical disease.

<p>Hypertension is common and constitutes an increased risk of morbidity and mortality of cardiovascular disease. Antihypertensive treatment will reduce this risk; the individual patient's response to treatment, however, is difficult to predict.</p><p>Patients with hypertension and left ventricular hypertrophy were randomized to monotherapy with either the angiotensin II type 1 receptor antagonist irbesartan or the beta-adrenoreceptor blocker atenolol, and followed for three months. The aim was to determine whether gene polymorphisms in the renin-angiotensin-aldosterone system were related to the response to treatment.</p><p>The ACE II genotype was associated with the most pronounced diastolic blood pressure response, while the aldosterone synthase (CYP11B2) -344 TT genotype showed the greatest systolic blood pressure response. The angiotensinogen 174 TM genotype showed the most pronounced regression in left ventricular mass, independent of the change in blood pressure. These associations were exhibited only in response to treatment with the angiotensin II type 1 receptor antagonist irbesartan.</p><p>In a sample of apparently healthy subjects, those with both the D allele and the angiotensinogen 174 TM variant in combination showed a decreased endothelium-dependent vasodilation.</p><p>These results suggest that the response to antihypertensive treatment is associated with polymorphisms in the genes reflective of the pathophysiological pathway the drug targets. The present study is an encouragement for future investigation, such as large scale studies of multiple polymorphisms and combinations thereof in an attempt to identify a panel of genotypes that can be used as a predictor of an individual patient's response to anithypertensive treatment.</p>

Hypertension is common and constitutes an increased risk of morbidity and mortality of cardiovascular disease. Antihypertensive treatment will reduce this risk; the individual patient's response to treatment, however, is difficult to predict. Patients with hypertension and left ventricular hypertrophy were randomized to monotherapy with either the angiotensin II type 1 receptor antagonist irbesartan or the beta-adrenoreceptor blocker atenolol, and followed for three months. The aim was to determine whether gene polymorphisms in the renin-angiotensin-aldosterone system were related to the response to treatment. The ACE II genotype was associated with the most pronounced diastolic blood pressure response, while the aldosterone synthase (CYP11B2) -344 TT genotype showed the greatest systolic blood pressure response. The angiotensinogen 174 TM genotype showed the most pronounced regression in left ventricular mass, independent of the change in blood pressure. These associations were exhibited only in response to treatment with the angiotensin II type 1 receptor antagonist irbesartan. In a sample of apparently healthy subjects, those with both the D allele and the angiotensinogen 174 TM variant in combination showed a decreased endothelium-dependent vasodilation. These results suggest that the response to antihypertensive treatment is associated with polymorphisms in the genes reflective of the pathophysiological pathway the drug targets. The present study is an encouragement for future investigation, such as large scale studies of multiple polymorphisms and combinations thereof in an attempt to identify a panel of genotypes that can be used as a predictor of an individual patient's response to anithypertensive treatment.

Resumo não disponível.